These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19238691)

  • 1. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan.
    Chang HC; Tang CH; Tsai SJ; Yen FC; Su KP
    J Clin Psychiatry; 2009 Jan; 70(1):141. PubMed ID: 19238691
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health resource utilization associated with switching to risperidone long-acting injection.
    Young CL; Taylor DM
    Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
    Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH
    Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan.
    Chang HC; Tang CH; Huang ST; McCrone P; Su KP
    J Psychiatr Res; 2012 Jun; 46(6):751-6. PubMed ID: 22440883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan.
    Fan SJ; Lu N; Chang HC; Tang CH; Huang KC
    Int Clin Psychopharmacol; 2018 Jul; 33(4):204-212. PubMed ID: 29489495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
    Chan HW; Huang CY; Feng WJ; Yen YC
    Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
    Willis M; Svensson M; Löthgren M; Eriksson B; Berntsson A; Persson U
    Eur J Health Econ; 2010 Dec; 11(6):585-94. PubMed ID: 20084535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukopenia during therapy with risperidone long-acting injectable: two case reports.
    Uzun S; Kozumplik O; Jakovljević M; Folnegović-Smalc V
    J Clin Psychopharmacol; 2008 Dec; 28(6):713-4. PubMed ID: 19011449
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
    Taylor M; Currie A; Lloyd K; Price M; Peperell K
    J Psychopharmacol; 2008 Mar; 22(2):128-31. PubMed ID: 18308820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
    Moore DB; Kelly DL; Sherr JD; Love RC; Conley RR
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S17-9. PubMed ID: 9872689
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost effectiveness of long-acting risperidone in Sweden.
    Hensen M; Heeg B; Löthgren M; van Hout B
    Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.